What to Know Before Signing With an MCO

Oncology NEWS InternationalOncology NEWS International Vol 17 No 7
Volume 17
Issue 7

For some oncology practices, it makes sense to contract with a managed care organization (MCO)-a contract simply enables you to treat enrollees of an MCO.

ABSTRACT: Pay special attention to provisions that spell out the services to be furnished, the payment amounts, and the terms of payment.

For some oncology practices, it makes sense to contract with a managed care organization (MCO)-a contract simply enables you to treat enrollees of an MCO.

Typically, the payment method under a managed care contract for oncology services is discounted charges, with the amount of the discount negotiated between the practice and the MCO.

However, such contracts are complicated and need to be reviewed carefully. Pay special attention to provisions that spell out the services to be furnished, the payment amounts, and the terms of payment.

It is also important to have a complete understanding of the MCO’s payment for each CPT code.

Five Important Questions to Ask

1. How important is this contract to your practice? The answer determines what the contract means in terms of your revenue and expenses, and leads to another question: What are your alternatives to this contract?

2. How does the contract define “medically necessary” care? It is vital to understand if the contract uses an objective standard, such as a “prudent physician” standard, or if it gives the MCO wide flexibility in determining what is medically necessary treatment.

3. Does the MCO have an obligation to pay you promptly? Make sure that the contract includes a specific payment period, and the MCO should agree to pay interest if it delays payment beyond the agreed-to period. Many states have laws requiring prompt payment.

4. Can the MCO change reimbursement terms unilaterally? If so, make sure that the MCO is required to provide you notice of any such reimbursement changes.

5. How can you terminate the contract? Make sure there is adequate room for terminating the contract if, for instance, the MCO breaches its agreement in any way. Also, ask whether the MCO is obligated to provide notice of your rights to terminate every year.

Related Videos
Experts on multiple myeloma
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Experts on multiple myeloma
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma